Australia's Self-Developed New Coronavirus Vaccine Announces Successful Early Trials

According to the Australian New World Media, the University of Queensland (UQ) new coronavirus pneumonia virus vaccine has played a role in animal trials, and it did not produce serious side effects in early human studies. This shows that it can overcome the The hope of the virus.

University of Queensland scientists release data from preclinical trials of coronavirus vaccine
Just as the new crown vaccine tested by the Oxford University and AstraZeneca Pharmaceuticals in the United Kingdom is expected to be submitted to regulatory agencies for approval by the end of 2020, the University of Queensland's new crown vaccine researchers also said that all the results so far indicate that the Australian vaccine candidate is Safe, and 'may provide protection against the new coronavirus.'

It is understood that unlike the AstraZeneca chimpanzee adenovirus vaccine at Oxford University, UQ's vaccine uses the so-called 'molecular clamp' technology.

The UQ drug candidate has been undergoing human trials since early July. Although it lags behind the Oxford University vaccine candidate in the testing process, most experts believe it is the most promising of the few Australian vaccines under development.

Scientists at the University of Queensland today released pre-clinical information about the vaccine, showing that the vaccine can trigger the immune system to prevent the disease.

During the trial, the Kunda University R&D team injected a certain dose of vaccine into hamsters, and then exposed them to the new coronavirus environment to test whether the drug can stimulate the required immune response.

UQ Scientists are 'Very Optimistic' about the Early Results of its Vaccine Trial

Experimental results showed that the candidate vaccine triggered the animal's immune response, and the disease symptoms were also 'significantly reduced'.

New data from a Dutch laboratory shows that the highly anticipated vaccine (called S-clamp) can protect hamsters when exposed to SARS-CoV-2 (the virus that causes COVID-19).

UQ scientist Keith Chappell said that the early results of the first human trial of 120 healthy adults in Brisbane were also promising. After a dose of the vaccine, no serious complications were caused.

'All the results so far indicate that this vaccine is safe and is likely to be able to prevent infection and relieve symptoms of infection. We can confidently say that in hamsters, the vaccine causes a more neutralizing stronger immune response than in humans. Human infections in the real world are different from hamsters in the laboratory, but we hope there will be similarities between them. These results are pointing in the right direction. The vaccine looks really good,' Chappell said.

Associate Professor Chappell is a member of a research team in Brisbane who has been studying vaccine candidates for the past 7 months. He introduced the latest findings of vaccines to 3,000 members of the International Society of Vaccines through the Zoom connection overnight.

Chappell said that vaccine trials on hamsters found that the two doses of the vaccine 'did well' in providing protection. All the results so far indicate that this vaccine is safe. 'I think we should eliminate this virus globally through social distancing, contact tracing and effective vaccines. I believe this is an achievable goal. Regarding vaccines, our goal should be to provide protection better than natural exposure,' Professor Chappell said.

If an effective vaccine can be produced to immunize SARS-CoV-2, this will be a major achievement, because there is no effective vaccine against the virus so far.

Professor Chappell’s colleague Trent Munro is also working on S-clamp. He said that it is important that researchers have shown that their vaccine candidates have the potential to achieve 'scale production' of millions. 'Everything we have seen so far gives us the confidence to continue,' Professor Munro said.

The University of Queensland's new coronavirus vaccine preclinical research data is gratifying
the 120 participants in the first human trial of the vaccine were healthy adults between the ages of 18 and 55. They have received at least one dose of vaccination and no safety issues have arisen so far.

'Everything is going very well,' Professor Munro said.

Queensland Innovation Minister Kate Jones described the latest trial data as 'a huge milestone in Queensland's vaccine development'.

According to an agreement signed with the University of Queensland, the Australian biotechnology company CSL is already preparing to step up the production of millions of doses of the vaccine at its Melbourne plant. Once trials show that the vaccine is safe and effective, it can begin mass production.

Researchers at the University of Queensland say that if the vaccine is considered safe and effective, up to 10 million doses of vaccine can be produced at a time.

'The Daily Mail' reported that if things go well, the public may be vaccinated at some stage next year.
Currently, there are more than 150 COVID-19 vaccines under development, some of which have been used in large-scale human trials, such as drug candidates from Oxford University.

Scientists have full confidence in Australia-developed drug candidates that have reached an agreement with Australian vaccine manufacturer CSL.

It is reported that the federal government has not yet reached a formal agreement with the University of Queensland. However, it is understood that if Australians think the vaccine is safe and effective, it will be the first people to receive the vaccine.

Federal Deputy Chief Medical Officer Michael Kidd described UQ's results as 'promising'. He told Channel Nine on Wednesday, 'This is indeed very good news, especially from Australia.'

He said, 'We have some top vaccine researchers from all over the world working in our country. They are working hard to find a vaccine for COVID-19 and are very happy to see these early results come out.'